Nkarta is a cash-rich clinical-stage cell-therapy company whose entire remaining franchise sits on a single allogeneic candidate, and the market is no longer willing to pay for the science until someone sees patients. The company abandoned its oncology program after a weaker acute-myeloid-leukemia cohort and redirected the platform toward B-cell autoimmune disease. What changed this summer is not a readout. It is the first public appointment to show whether an off-the-shelf natural-killer product can reset an autoimmune immune system from a community clinic rather than an academic ward. Two oral abstracts and a poster were accepted for the American College of Rheumatology meeting in early November, covering safety across the Ntrust basket and early activity in myositis and scleroderma.
The balance sheet is the other half of the argument. Cash, equivalents, restricted cash and investments totaled $243 million at late June. That stockpile is already down from the year-end securities book, and the equity trades near a $203 million capitalization. That gap is the market assigning little to no value to the lead candidate after subtracting the long-dated lease stack. First-half operating cash use of $52 million already annualizes to a burn that lands closer to late twenty twenty-eight than the official into-twenty twenty-nine guide if the second-half run-rate holds. No at-the-market shares printed in the half, which is the correct choice at a below-cash quote, and three million pre-funded warrants remain unexercised.
The counterargument is already visible in the income statement. Research spending stepped up as patients entered the four-billion-cell dose cohort, and a non-cash impairment of $8 million on equipment and leased space shows the company shrinking a manufacturing footprint built for a broader pipeline. The next several months resolve a single question. Does the November dataset show deep B-cell depletion and early clinical activity with an outpatient safety profile that community rheumatologists can actually use, or does it show a tolerable but shallow effect that leaves Nkarta as a shrinking cash stub?